CN102124107A - 使用短干扰核酸(siNA)的RNA干扰介导的前蛋白转化酶枯草杆菌蛋白酶Kexin9(PCSK9)基因表达的抑制 - Google Patents

使用短干扰核酸(siNA)的RNA干扰介导的前蛋白转化酶枯草杆菌蛋白酶Kexin9(PCSK9)基因表达的抑制 Download PDF

Info

Publication number
CN102124107A
CN102124107A CN2007800269961A CN200780026996A CN102124107A CN 102124107 A CN102124107 A CN 102124107A CN 2007800269961 A CN2007800269961 A CN 2007800269961A CN 200780026996 A CN200780026996 A CN 200780026996A CN 102124107 A CN102124107 A CN 102124107A
Authority
CN
China
Prior art keywords
nucleotide
nucleotides
sina
strand
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2007800269961A
Other languages
English (en)
Chinese (zh)
Inventor
J·麦斯维根
V·贾哈夫
C·瓦吉斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sirna Therapeutics Inc
Original Assignee
Sirna Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/487,788 external-priority patent/US20070173473A1/en
Application filed by Sirna Therapeutics Inc filed Critical Sirna Therapeutics Inc
Publication of CN102124107A publication Critical patent/CN102124107A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2007800269961A 2006-07-17 2007-07-17 使用短干扰核酸(siNA)的RNA干扰介导的前蛋白转化酶枯草杆菌蛋白酶Kexin9(PCSK9)基因表达的抑制 Pending CN102124107A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/487,788 US20070173473A1 (en) 2001-05-18 2006-07-17 RNA interference mediated inhibition of proprotein convertase subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA)
US86136906P 2006-11-28 2006-11-28
PCT/US2007/073723 WO2008011431A2 (en) 2006-07-17 2007-07-17 Rna interference mediated inhibition of proprotein convertase subtilisin kexin 9 (pcsk9) gene expression using short interfering nucleic acid (sina)

Publications (1)

Publication Number Publication Date
CN102124107A true CN102124107A (zh) 2011-07-13

Family

ID=38957565

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800269961A Pending CN102124107A (zh) 2006-07-17 2007-07-17 使用短干扰核酸(siNA)的RNA干扰介导的前蛋白转化酶枯草杆菌蛋白酶Kexin9(PCSK9)基因表达的抑制

Country Status (6)

Country Link
EP (1) EP2052079A2 (enExample)
JP (1) JP2010503382A (enExample)
CN (1) CN102124107A (enExample)
AU (1) AU2007275365A1 (enExample)
CA (1) CA2658183A1 (enExample)
WO (1) WO2008011431A2 (enExample)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104508488A (zh) * 2012-05-25 2015-04-08 佐拉生物科学公司 针对前蛋白转化酶枯草溶菌素/Kexin 9抑制的灵敏的功效性和特异性生物标志
CN108977446A (zh) * 2011-11-18 2018-12-11 阿尔尼拉姆医药品有限公司 修饰的RNAi试剂
CN109957565A (zh) * 2017-12-26 2019-07-02 广州市锐博生物科技有限公司 一种修饰的siRNA分子及其应用
CN109957567A (zh) * 2017-12-26 2019-07-02 广州市锐博生物科技有限公司 一种抑制PCSK9基因表达的siRNA分子及其应用
CN109666727B (zh) * 2018-12-29 2020-11-06 中国药科大学 一种高活性抑制pcsk9表达的微小rna的用途
WO2020233655A1 (zh) * 2019-05-22 2020-11-26 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
CN115176011A (zh) * 2019-08-27 2022-10-11 赛诺菲 用于抑制pcsk9的组合物和方法
US11492620B2 (en) 2017-12-01 2022-11-08 Suzhou Ribo Life Science Co., Ltd. Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof
CN115322991A (zh) * 2015-05-06 2022-11-11 阿尔尼拉姆医药品有限公司 因子XII、激肽释放酶B、血浆夫列契因子1和激肽原1 iRNA组合物及其使用方法
WO2023284763A1 (zh) * 2021-07-16 2023-01-19 苏州瑞博生物技术股份有限公司 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途
US11633482B2 (en) 2017-12-29 2023-04-25 Suzhou Ribo Life Science Co., Ltd. Conjugates and preparation and use thereof
US11660347B2 (en) 2017-12-01 2023-05-30 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing same, preparation method, and use thereof
CN116889627A (zh) * 2019-03-20 2023-10-17 雷杰纳荣制药公司 用固醇调节元件结合转录因子1(srebf1)抑制剂治疗脂质水平升高
US11896674B2 (en) 2018-09-30 2024-02-13 Suzhou Ribo Life Science Co., Ltd. SiRNA conjugate, preparation method therefor and use thereof
US11918600B2 (en) 2018-08-21 2024-03-05 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof
CN117757794A (zh) * 2016-03-07 2024-03-26 美国政府(由卫生和人类服务部的部长所代表) 微小rna及其使用方法
WO2024104416A1 (zh) * 2022-11-17 2024-05-23 北京福元医药股份有限公司 抑制SCAP基因表达的siRNA、其缀合物和药物组合物及用途
US12083142B2 (en) 2017-12-01 2024-09-10 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
US12084661B2 (en) 2017-12-01 2024-09-10 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
US12428642B2 (en) 2017-12-01 2025-09-30 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate comprising the same, preparation method and use thereof
US12497622B2 (en) 2019-05-22 2025-12-16 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7935812B2 (en) 2002-02-20 2011-05-03 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
US7404969B2 (en) * 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
WO2007086883A2 (en) 2005-02-14 2007-08-02 Sirna Therapeutics, Inc. Cationic lipids and formulated molecular compositions containing them
SG171676A1 (en) * 2006-05-11 2011-06-29 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expression of the pcsk9 gene
MX2009003729A (es) * 2006-10-09 2009-04-22 Santaris Pharma As Copuestos antagonistas de acido ribonucleico para la modulacion de proproteina convertasa subtilisina/kexina tipo 9a.
US8093222B2 (en) 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
JP2010510807A (ja) 2006-11-27 2010-04-08 アイシス ファーマシューティカルズ， インコーポレーテッド 高コレステロール血症を治療するための方法
EP2245039A4 (en) * 2008-01-31 2012-06-06 Alnylam Pharmaceuticals Inc OPTIMIZED METHODS FOR EXPORING DSRNA TO TARGET THE PCSK9 GEN
US20110065644A1 (en) * 2008-03-09 2011-03-17 Intradigm Corporation Compositions comprising human pcsk9 and apolipoprotein b sirna and methods of use
WO2009127680A1 (en) * 2008-04-16 2009-10-22 Santaris Pharma A/S Pharmaceutical composition comprising anti pcsk9 oligomers
CA2635187A1 (en) * 2008-06-05 2009-12-05 The Royal Institution For The Advancement Of Learning/Mcgill University Oligonucleotide duplexes and uses thereof
US8790664B2 (en) 2008-09-05 2014-07-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Multimodular assembly useful for intracellular delivery
WO2010147992A1 (en) 2009-06-15 2010-12-23 Alnylam Pharmaceuticals, Inc. Methods for increasing efficacy of lipid formulated sirna
EP2442792A4 (en) 2009-06-15 2015-12-23 Alnylam Pharmaceuticals Inc TESTING GENE PCSK9 LIPID-FORMULATED DSRNA
WO2011009697A1 (en) 2009-07-21 2011-01-27 Santaris Pharma A/S Antisense oligomers targeting pcsk9
WO2011038031A1 (en) 2009-09-22 2011-03-31 Alnylam Pharmaceuticals, Inc. Dual targeting sirna agents
EP3721943A1 (en) * 2009-12-23 2020-10-14 Novartis AG Lipids, lipid compositions and methods of using them
EP2694670B1 (en) 2011-04-08 2017-07-19 Bio-Rad Laboratories, Inc. Pcr reaction mixtures with decreased non-specific activity
JP6002382B2 (ja) * 2011-12-07 2016-10-05 株式会社バイオシンクタンク 遺伝子発現阻害剤及び阻害方法
HUE035887T2 (en) 2012-12-05 2018-05-28 Alnylam Pharmaceuticals Inc PCSK9 iRNA preparations and methods for their use
DK3013959T3 (da) 2013-06-27 2020-02-17 Roche Innovation Ct Copenhagen As Antisense-oligomerer og konjugater målrettet pcsk9
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
FR3014695A1 (enExample) * 2013-12-17 2015-06-19 Kymab Ltd
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
GB2537614A (en) * 2015-04-20 2016-10-26 Heart Biotech Ltd Formulations for inhibition of PCSK9 for the treatment of hypercholesterolemia
CN108348541A (zh) 2015-08-25 2018-07-31 阿尔尼拉姆医药品有限公司 用于治疗前蛋白转化酶枯草杆菌蛋白酶kexin(pcsk9)基因相关障碍的方法和组合物
BR112018015164A2 (pt) * 2016-01-26 2018-12-26 Nissan Chemical Corp oligonucleotídeo de fita simples
EP3440463B1 (en) * 2016-04-05 2020-07-08 Université de Strasbourg Intra-droplet surface engineering to capture a molecular target
JP7129702B2 (ja) * 2016-09-29 2022-09-02 国立大学法人 東京医科歯科大学 オーバーハングを有する二本鎖核酸複合体
JP7461886B2 (ja) * 2017-11-13 2024-04-04 サイレンス・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 標的遺伝子の発現を抑制するためのジチオリン酸結合を含む核酸
WO2019126990A1 (zh) * 2017-12-26 2019-07-04 广州市锐博生物科技有限公司 一种抑制PCSK9基因表达的siRNA分子及其应用
CA3097585A1 (en) * 2018-04-18 2019-10-24 Dicerna Pharmaceuticals, Inc. Pcsk9 targeting oligonucleotides for treating hypercholesterolemia and related conditions
WO2021185765A1 (en) 2020-03-16 2021-09-23 Argonaute RNA Limited Antagonist of pcsk9
JP2024531728A (ja) * 2021-09-14 2024-08-29 アルゴノート アールエヌエー リミテッド 心血管疾患の処置
WO2024228030A2 (en) * 2023-05-04 2024-11-07 Argonaute RNA Limited Dual silencing

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070173473A1 (en) * 2001-05-18 2007-07-26 Sirna Therapeutics, Inc. RNA interference mediated inhibition of proprotein convertase subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA)
US20060148743A1 (en) * 2001-05-18 2006-07-06 Vasant Jadhav RNA interference mediated inhibition of histone deacetylase (HDAC) gene expression using short interfering nucleic acid (siNA)
EP2336317B1 (en) * 2003-06-13 2019-09-11 Alnylam Europe AG Double-stranded ribonucleic acid with increased effectiveness in an organism
US20090130691A1 (en) * 2005-09-16 2009-05-21 Institut De Recherches Cliniques De Montreal Screening proteinase modulators using a chimeric protein and ski-i proprotein convertase substrates and inhibitors
WO2007136989A2 (en) * 2006-05-05 2007-11-29 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of dgat2

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108977446A (zh) * 2011-11-18 2018-12-11 阿尔尼拉姆医药品有限公司 修饰的RNAi试剂
CN104508488A (zh) * 2012-05-25 2015-04-08 佐拉生物科学公司 针对前蛋白转化酶枯草溶菌素/Kexin 9抑制的灵敏的功效性和特异性生物标志
CN115322991A (zh) * 2015-05-06 2022-11-11 阿尔尼拉姆医药品有限公司 因子XII、激肽释放酶B、血浆夫列契因子1和激肽原1 iRNA组合物及其使用方法
CN117757794A (zh) * 2016-03-07 2024-03-26 美国政府(由卫生和人类服务部的部长所代表) 微小rna及其使用方法
US12083142B2 (en) 2017-12-01 2024-09-10 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
US11660347B2 (en) 2017-12-01 2023-05-30 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing same, preparation method, and use thereof
US12428642B2 (en) 2017-12-01 2025-09-30 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate comprising the same, preparation method and use thereof
US12274752B2 (en) 2017-12-01 2025-04-15 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing same, preparation method, and use thereof
US12084661B2 (en) 2017-12-01 2024-09-10 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
US11492620B2 (en) 2017-12-01 2022-11-08 Suzhou Ribo Life Science Co., Ltd. Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof
CN109957567A (zh) * 2017-12-26 2019-07-02 广州市锐博生物科技有限公司 一种抑制PCSK9基因表达的siRNA分子及其应用
CN109957565B (zh) * 2017-12-26 2023-04-07 广州市锐博生物科技有限公司 一种修饰的siRNA分子及其应用
CN109957567B (zh) * 2017-12-26 2022-09-23 阿格纳生物制药有限公司 一种抑制PCSK9基因表达的siRNA分子及其应用
CN109957565A (zh) * 2017-12-26 2019-07-02 广州市锐博生物科技有限公司 一种修饰的siRNA分子及其应用
US11633482B2 (en) 2017-12-29 2023-04-25 Suzhou Ribo Life Science Co., Ltd. Conjugates and preparation and use thereof
US11918600B2 (en) 2018-08-21 2024-03-05 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof
US11896674B2 (en) 2018-09-30 2024-02-13 Suzhou Ribo Life Science Co., Ltd. SiRNA conjugate, preparation method therefor and use thereof
US12496347B2 (en) 2018-12-28 2025-12-16 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
CN109666727B (zh) * 2018-12-29 2020-11-06 中国药科大学 一种高活性抑制pcsk9表达的微小rna的用途
CN116889627A (zh) * 2019-03-20 2023-10-17 雷杰纳荣制药公司 用固醇调节元件结合转录因子1(srebf1)抑制剂治疗脂质水平升高
WO2020233655A1 (zh) * 2019-05-22 2020-11-26 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
US12497622B2 (en) 2019-05-22 2025-12-16 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
CN115176011A (zh) * 2019-08-27 2022-10-11 赛诺菲 用于抑制pcsk9的组合物和方法
CN115176011B (zh) * 2019-08-27 2025-11-11 赛诺菲 用于抑制pcsk9的组合物和方法
WO2023284763A1 (zh) * 2021-07-16 2023-01-19 苏州瑞博生物技术股份有限公司 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途
WO2024104416A1 (zh) * 2022-11-17 2024-05-23 北京福元医药股份有限公司 抑制SCAP基因表达的siRNA、其缀合物和药物组合物及用途

Also Published As

Publication number Publication date
CA2658183A1 (en) 2008-01-24
EP2052079A2 (en) 2009-04-29
WO2008011431A2 (en) 2008-01-24
WO2008011431A3 (en) 2008-07-17
AU2007275365A1 (en) 2008-01-24
JP2010503382A (ja) 2010-02-04
WO2008011431A8 (en) 2009-11-05

Similar Documents

Publication Publication Date Title
CN102124107A (zh) 使用短干扰核酸(siNA)的RNA干扰介导的前蛋白转化酶枯草杆菌蛋白酶Kexin9(PCSK9)基因表达的抑制
EP1931781B1 (en) Chemically modified short interfering nucleic acid molecules that mediate rna interference
US20070173473A1 (en) RNA interference mediated inhibition of proprotein convertase subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA)
US20110313024A1 (en) RNA INTERFERENCE MEDIATED INHIBITION OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US7897753B2 (en) RNA interference mediated inhibition of XIAP gene expression using short interfering nucleic acid (siNA)
US7662952B2 (en) RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acid (siNA)
KR20080079329A (ko) 짧은 간섭 핵산(ｓｉＮＡ)을 사용한 Ｃ형 간염바이러스(ＨＣＶ) 유전자 발현의 ＲＮＡ 간섭 매개 억제
WO2006128141A2 (en) Rna interference mediated inhibition of stromal cell-derived factor-1 (sdf-1) gene expression using short interfering nucleic acid (sina)
US8258288B2 (en) RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA)
WO2008011467A2 (en) Rna interference mediated inhibition of sterol regulatory element-binding protein 1 (srebp1) gene expression using short interfering nucleic acid (sina)
CN102292443A (zh) 使用短干扰核酸(siNA)的RNA干扰介导的上皮钠通道(ENaC)基因表达的抑制
WO2007147143A2 (en) Rna interference mediated inhibition of 11 beta-hydroxysteroid dehydrogenase-1 (11 beta-hsd-1) gene expression using short interfering nucleic acid (sina)
WO2007092059A2 (en) Rna interference mediated inhibition of influenza virus gene expression using short interfering nucleic acid
US20060287267A1 (en) RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA)
WO2009055445A2 (en) RNA INTERFERENCE MEDIATED INHIBITION OF RESPIRATORY SYNCYTIAL VIRUS (RSV) EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2009504190A (ja) Ｒｎａ干渉を媒介する化学修飾低分子干渉核酸分子
CN101605892A (zh) Rna干扰介导的丙型肝炎病毒的抑制
WO2009156853A2 (en) Compounds, compositions, and methods useful for modulating the expression of histone deacetylase (hdac) gene expression and/or activity
US20070179104A1 (en) RNA interference mediated inhibition of winged helix nude (WHN) gene expression using short interfering nucleic acid (siNA)
JP2009509566A (ja) 低分子干渉核酸を用いた、ｒｎａ干渉によって媒介される、インフルエンザウイルス遺伝子発現の阻害
WO2006078798A2 (en) RNA INTERFERENCE MEDIATED INHIBITION OF RETINOBLASTOMA (RB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2007120527A2 (en) Rna interference mediated inhibition of respiratory syncytial virus (rsv) expression using short interfering nucleic acid (sina)

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110713